News & Events

Akesiss is proud to announce the launch of their new division− CARVO dedicated to Cardiac Care. CARVO will focus exclusively on Cardiology Segment offering unique solutions for prevention& management of Hypertension, Heart Failure etc. The new range of products from CARVO is aimed to support Cardiac patients having cardiac ailments with newer molecules as well as products at affordable prices. Mr. Kesavan Unni will be heading the division as General Manager-Marketing & Sales. With more than 25 years of extensive experience he has gained in-depth knowledge of Pharma marketing particularly in Cardiology Segment. Associated with several well− known companies like Ajanta Pharma, Bal Pharma, Cipla, Micro Labs and Sun Pharma. Prior to his assignment with Akesiss he was with Emcure as DGM− Sales & Marketing. CARVOis well structured in terms of manpower resource and effective Product Portfolio. Major brands under CARVO Division are Chlohat, Telmurix, Metopot, Toracor, Olright, and Olright− AM. Some of the products are first of its kind in the respective segments. The launch of a dedicated division will help to strengthen its position in these segments as well as in the domestic market, says Mr. Ashok Kumar− Managing Director.

Akesiss announces the launch of multispecialty division in three states− Odisha, Andhra Pradesh & Rest of Maharashtra with their innovative product portfolio. The objective of this special operation isto gain market share in gynecology, general medicine & orthopedics in the respective states. The company has already recruited employees at all level for full fledged marketing operation. Every employee has undergone special product and skills development training program to enhance their knowledge and competency. The company has already established depot and office in Pune and Hyderabad to optimally support the large field force.

Company has also identified these locations as a center to support operations in northern states of India. Mr. Ashok Kumar, managing director-Akesiss pharma is expecting that the new venture will boost overall performance of the organization.

As a responsible corporate, Akesiss believes in creation of values for all it's employees and constantly endeavors to work towards boosting employee satisfaction level, moral & also encourage an open and congenital work environment. With the overwhelming growth of the company and it's divisions, Akesiss has gone for modernizing and expanding infrastructures to ensure appropriate support to field force from Head Office. The new office is equipped with modern amenities for effective support to all the functional cells like Human Resource, Marketing, Finance, Supply chain, Distribution etc.

Akesiss is proud of launching its third division LAZO - Akesiss has set a successful trend in specialities like Gynecology, Diabetology, Cardiology & ENT with its two divisions Zalvo & Glyvo. Today, Akesiss is proud of launching its third division LAZO, exploring the fast growing therapeutic segments like Orthopedics, Surgical specialities and Dermatology. LAZO is well structured in terms of Manpower strength and the latest and unique Product portfolio.

One of the major objectives of LAZO is to provide affordable treatment options, especially in chronic speciality like Orthopedics. As a part of this initiative, many brands in this segment like WAKFREE, LOXCAM & RABIPOT are launched as the most economical brands in India which are upto 50 % economical than the competitors

It is a new historical beginning for Akesiss in the New Year - 2010. Akesiss is always Quality Conscious and is constantly striving for a better customer service through our Quality products and Quality Services. We are extremely delighted to share that, Akesiss is now An ISO 9001-2008 Certified company. The ISO certification holds more prominence as it is certified by the World's leading Quality Management system Certification body, Bureau Verities of France in accreditation with UKAS of United Kingdom (U.K). The certification process from Bureau Veritas follows the stringent norms of Quality Management which is followed by the leading companies of the world. This mile stone is also significant, because, Akesiss will be among very few pharmaceutical companies in India to achieve this, in a very short period of operation.

Akesiss has launched the Revolutionary Mineral Transporter OROTATE (Calcium Orotate 740 mg) that provides up to 95% absorption which is highest amongst the available calcium preparations. Akesiss being the only Pharma Company in India to focus OROTATE in Gynecology segment, the company foresees the scope of making this as a leading brand in this segment.

Akesiss conducted its first Cardio-Diabetology update at Hotel Carlton, Kodaikanal on 17, 18, 19 April 2009. The update was attended by leading Diabetologists, Endocrinologists and Physicians of Kerala and Tamilnadu with scientific committee presided by world renowned experts− Prof.A.Ramachandran and Prof. G. Vijayaraghavan (Padmashree awardee). The scientific sessions were highly appreciated by the delegates as it provided a suitable forum to interact and provide the apt solutions for the newer challenges of Diabetes, Cardio - Vascular diseases and its Prevention.

The Objective of "Akesiss Cardio - Diabetology Updates"

There is an explosive rise in the Epidemic of Diabetes world over and every one is concerned as India ranks number one in Diabetes Prevalence. Needless to mention the economic burden induced by Diabetes related Complications in which Cardio - Nephro related areas are raising threat even to the newer age group in India. We at Akesiss realize the seriousness and urgency to prevent and protect the newer generation from this menace and improving the quality of life of all Diabetics. Also, the treatment and management modalities are undergoing a massive change, on a regular basis, hence there is a need for a platform to explore and exchange the information among experts which would facilitate newer solutions for the prevention and management of Diabetes. Akesiss is committed in setting up a nation wide network of scientific community on a common platform to facilitate research activities to provide practical and effective solutions to prevent and protect the newer generations from the Epidemic of Diabetes and its Complications.